Impact of chemotherapy on medium-term physical function and activity of older breast cancer survivors, and associated biomarkers. Issue 1 (January 2017)
- Record Type:
- Journal Article
- Title:
- Impact of chemotherapy on medium-term physical function and activity of older breast cancer survivors, and associated biomarkers. Issue 1 (January 2017)
- Main Title:
- Impact of chemotherapy on medium-term physical function and activity of older breast cancer survivors, and associated biomarkers
- Authors:
- Extermann, Martine
Leeuwenburgh, Christiaan
Samiian, Laila
Sehovic, Marina
Xu, Jinze
Cubitt, Christopher
Jacobsen, Paul B.
Pahor, Marco
Grobmyer, Stephen R.
Manini, Todd M. - Abstract:
- Abstract: Objective : Chemotherapy is less often prescribed in older individuals due to concerns about post-treatment morbidity and quality of life. We evaluated the physical performance of breast cancer survivors treated with and without adjuvant chemotherapy. Materials and Methods : We conducted a case–control study in 56 estrogen receptor positive breast cancer survivors (BCS) on adjuvant aromatase inhibitors 1–2 years after definitive surgery. Cases had received adjuvant chemotherapy (n = 27; age 70.5 ± 3.6 years) versus age-matched controls who had not (n = 29; age 70.0 ± 4.3 years). Measures of grip strength, physical activity and performance, walking speed, fatigue, and self-reported physical function were collected. Biological correlates of inflammation, frailty and markers of DNA and RNA oxidation were compared. Results : Grip strength (controls: 21 ± 7.4 vs. cases: 29.7 ± 5.0 kg, p = 0.20), physical activity (5403 ± 3204 vs. 6801 ± 9320 steps/day, p = 0.45), physical performance (short physical performance battery score: 10.1 ± 1.8 vs. 10.4 ± 1.1, p = 0.52) and long-distance walking speed (1.2 ± 0.21 vs. 1.3 ± 0.41 m/s, p = 0.17) were similar between the two groups. Self-reported physical function was marginally lower in cases than controls (controls: 72 ± 24 vs. cases: 57 ± 34 AU, p = 0.07). Fatigue disruptiveness was not different between groups (controls: 11.1 ± 13.0 vs. cases: 15.7 ± 16.2 AU, p = 0.24). Similarly, the inflammation, oxidation, and frailtyAbstract: Objective : Chemotherapy is less often prescribed in older individuals due to concerns about post-treatment morbidity and quality of life. We evaluated the physical performance of breast cancer survivors treated with and without adjuvant chemotherapy. Materials and Methods : We conducted a case–control study in 56 estrogen receptor positive breast cancer survivors (BCS) on adjuvant aromatase inhibitors 1–2 years after definitive surgery. Cases had received adjuvant chemotherapy (n = 27; age 70.5 ± 3.6 years) versus age-matched controls who had not (n = 29; age 70.0 ± 4.3 years). Measures of grip strength, physical activity and performance, walking speed, fatigue, and self-reported physical function were collected. Biological correlates of inflammation, frailty and markers of DNA and RNA oxidation were compared. Results : Grip strength (controls: 21 ± 7.4 vs. cases: 29.7 ± 5.0 kg, p = 0.20), physical activity (5403 ± 3204 vs. 6801 ± 9320 steps/day, p = 0.45), physical performance (short physical performance battery score: 10.1 ± 1.8 vs. 10.4 ± 1.1, p = 0.52) and long-distance walking speed (1.2 ± 0.21 vs. 1.3 ± 0.41 m/s, p = 0.17) were similar between the two groups. Self-reported physical function was marginally lower in cases than controls (controls: 72 ± 24 vs. cases: 57 ± 34 AU, p = 0.07). Fatigue disruptiveness was not different between groups (controls: 11.1 ± 13.0 vs. cases: 15.7 ± 16.2 AU, p = 0.24). Similarly, the inflammation, oxidation, and frailty markers did not present a significant difference between groups, except for vitamin D levels (p = 0.04). Conclusion : Older women who received chemotherapy reported having slightly lower physical function, but a similar physical performance compared to women who did not. These data suggest that older BCS treated with chemotherapy recover to an extent similar to survivors who only received hormonal therapy. … (more)
- Is Part Of:
- Journal of geriatric oncology. Volume 8:Issue 1(2017)
- Journal:
- Journal of geriatric oncology
- Issue:
- Volume 8:Issue 1(2017)
- Issue Display:
- Volume 8, Issue 1 (2017)
- Year:
- 2017
- Volume:
- 8
- Issue:
- 1
- Issue Sort Value:
- 2017-0008-0001-0000
- Page Start:
- 69
- Page End:
- 75
- Publication Date:
- 2017-01
- Subjects:
- Chemotherapy -- Elderly -- Physical function -- Breast cancer -- Survivorship -- Functional status -- Inflammation -- TNF-alpha -- IL-6 -- d-Dimers -- IGF-1 -- IGFBP-3 -- DNA oxidation -- RNA oxidation -- Vitamin D -- Albumin
Geriatric oncology -- Periodicals
Neoplasms -- Periodicals
Aged -- Periodicals
Geriatric oncology
Electronic journals
Periodicals
618.976994005 - Journal URLs:
- http://www.clinicalkey.com.au/dura/browse/journalIssue/18794068 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/18794068 ↗
http://www.sciencedirect.com/science/journal/18794068 ↗
http://www.sciencedirect.com/ ↗ - DOI:
- 10.1016/j.jgo.2016.09.004 ↗
- Languages:
- English
- ISSNs:
- 1879-4068
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 2239.xml